Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder

BMC Urology

Volumn 6, Issue , 2006, Pages

  Staack, Andrea ^a   Badendieck, Steffen ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; ROC CURVE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33748550328     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-6-19     Document Type: Article

References (47)

1. Society AC: Cancer Facts and Figures 2006. http://wwwcancerorg/docroot/ STT/stt_0asp 2006.
2. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I: Current concepts in biomarker technology for bladder cancers. Clin Chem 2000, 46:595-605.
3. Koenig F, Jung K, Schnorr D, Loening SA: Urinary markers of malignancy. Clin Chim Acta 2000, 297:191-205.
4. Vasala K, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003, 62:952-957.
5. Gontero P, Banisadr S, Frea B, Brausi M: Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 2004, 46:296-311.
6. Staack A, Koenig F, Daniltchenko D, Hauptmann S, Loening SA, Schnorr D, Jung K: Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. Urology 2002, 59:308-312.
7. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 2001, 57:675-679.
8. Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, Kinders RJ, Raitanen M, Meri S, Jokiranta TS: Complement factor H as a marker for detection of bladder cancer. Clin Chem 2005, 51:856-863.
9. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA: Four tumour markers for urinary bladder cancer - tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res 2005, 25:635-641.
10. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
11. Chen WT: Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 1992, 4:802-809.
12. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
13. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004, 49:179-186.
14. Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004, 16:558-564.
15. Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G, Dimopoulos C: MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 2001, 9:130-137.
16. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK: Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61:719-723.
17. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198.
18. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE: Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991, 51:2151-2157.
19. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989, 264:17374-17378.
20. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M: Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998, 77:650-655.
21. Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H: Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J Biol Chem 2000, 275:33008-33013.
22. Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA: Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 1996, 42:2043-2045.
23. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804.
24. Hemmerlein B, Johanns U, Halbfass J, Bottcher T, Heuser M, Radzun HJ, Thelen P: The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide. Int J Oncol 2004, 24:1069-1076.
25. Flisiak R, Jaroszewicz J, Lapinski TW, Flisiak I, Prokopowiczi D: Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol 2005, 11:6833-6838.
26. Keyszer G, Lambiri I, Keysser M, Keysser C, Nagel R, Burmester GR, Jung K: Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Z Rheumatol 1998, 57:392-398.
27. Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, Loening SA: Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997, 30:491-496.
28. Kramar A, Faraggi D, Fortune A, Reiser B: mROC: a computer program for combining tumour markers in predicting disease states. Comput Methods Programs Biomed 2001, 66:199-207.
29. Gordi T, Khamis H: Simple solution to a common statistical problem: interpreting multiple tests. Clin Ther 2004, 26:780-786.
30. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
31. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993, 53:5365-5369.
32. Kanayama H: Matrix metalloproteinases and bladder cancer. J Med Invest 2001, 48:31-43.
33. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A: Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000, 20:2009-2013.
34. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M: Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992, 7:77-83.
35. Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A: Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003, 9:5573-5581.
36. Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD: Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer 2006, 94:569-577.
37. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998, 160:1914-1918.
38. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001, 7:3113-3119.
39. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996, 78:2379-2387.
40. Jung K, Meisser A, Bischof P: Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005, 116:1000-1001.
41. Meisser A, Cohen M, Bischof P: Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005, 51:274-276.
42. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE: Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005, 344:147-149.
43. Friedel R, Diederichs F, Lindena J: Release and extracellular turnover of cellular enzymes. In Advances in clinical enzymology Edited by: Schmidt E, Schmidt FW, Trautschold I and Friedel R. Basel, Karger; 1979:70-105.
44. Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6:227-239.
45. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T: Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002, 86:1876-1883.
46. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006, 233:98-107.
47. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H: Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006, 52:838-844.